New Products Posted to GenomeWeb | GenomeWeb

Cepheid's BCR-ABL Ultra

Cepheid has begun shipping the CE-IVD marked Xpert BCR-ABL Ultra test to quantitate mRNA transcripts in patients with chronic myelogenous leukemia undergoing tyrosine kinase inhibitor treatment. The assay is an updated version of the Xpert BCR-ABL Monitor test that provides increased sensitivity, the firm said. It is aligned to the International Scale on a lot-to-lot basis, increasing reliability of comparisons between labs, and uses the Cepheid GeneXpert system to deliver results in less than two and a half hours.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.